Prescient Therapeutics unveils new data validating cancer cell therapy technology
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its...
Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting...
Biotech company Prescient Therapeutics has given investors a glimpse into the progress of it’s next-generation...
In an announcement made this morning, the Melbourne-based company revealed its OmniCAR platform continues to...
Prescient Therapeutics Limited (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell &...
Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell &...
ASX-listed oncology player, Prescient Therapeutics Limited (ASX:PTX) is developing personalised medicines for difficult to treat...
This year, the ASX healthcare index gained a little more than 10% year to date....
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as...
Australia-based clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has completed another action-packed year with a...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.